MM-II is an intra-articular bio lubricant injection which is being developed to provide symptomatic relief of mild-to-moderate osteoarthritis pain. The product is based on patent-protected technology licensed by Moebius Medical from the Hebrew University of Jerusalem, Technion Israel Institute of Technology and Hadassah Medical Centre. 

 

Sun pharma said initial clinical data showed superior efficacy and similar safety of MM-II vs the standard case which is hyaluronic acid for treatment of pain in osteoarthritis. Sun will be funding the clinical development of the molecule and will possess the worldwide commercialisation and manufacturing rights. MM-II is a novel non-opioid product, Sun said that leverages the physical properties of proprietary liposomes to lubricate arthritic knee joints, thereby reducing friction and wear, consequently leading to joint pain reduction.

 

Moebius Medical so far has completed a first-in-man clinical study at Hadassah Medical Center, Moebius Medical will conduct requisite pre-clinical studies, and will assume responsibility for product development and manufacturing through the end of Phase-II studies. Sun Pharma will assume responsibility for further clinical studies, regulatory submissions and product commercialization. Moebius Medical will receive an upfront payment, development-based and sales-based milestone payments, and tiered royalties on sales from Sun Pharma.